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ABSTRACT
TBLR1/TBL1XR1, a core component of the nuclear receptor corepressor (NCoR) 
complex critical for the regulation of multiple nuclear receptors, is a transcriptional 
coactivator of androgen receptor (AR) and functions as a tumor suppressor when 
expressed in the nucleus in prostate. Subcellular localization of a protein is critical 
for its function, and although TBLR1, as a transcriptional cofactor, has been primarily 
viewed as a nuclear protein, many cells also express variable levels of cytoplasmic 
TBLR1 and its cytoplasmic specific functions have not been studied. Prostate cancer 
(PCa) cells express moderately higher level of cytoplasmic TBLR1 compared to benign 
prostate cells. When comparing androgen-dependent (AD) to androgen-independent 
(AI) PCa, AI cells contain very high levels of TBLR1 cytoplasmic expression and 
low levels of nuclear expression. Overexpression of cytoplasmic TBLR1 in AD cells 
inhibits apoptosis induced by androgen deprivation therapy, either in an androgen free 
condition or in the presence of bicalutamide. Additionally, we identified a cytoplasmic 
specific isoform of TBLR1 (cvTBLR1) approximately 5 kDa lower in molecular weight, 
that is expressed at higher levels in AI PCa cells. By immunoprecipitation, we 
purified cvTBLR1 and using mass spectrometry analysis combined with N-terminal 
TMPP labeling and Edman degradation, we identified the cleavage site of cvTBLR1 
at amino acid 89, truncating the first 88 amino acids of the N-terminus of the full 
length protein. Functionally, cvTBLR1 expressed in the cytoplasm reduced apoptosis 
in PCa cells and promoted growth, migration, and invasion. Finally, we identified a 
nuclear export signal sequence for TBLR1 cellular localization by deletion and site-
directed mutagenesis. The roles of TBLR1 and cvTBLR1 provide novel insights into 
the mechanism of castration resistance and new strategies for PCa therapy. 
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INTRODUCTION
Prostate cancer (PCa) is an exceedingly prevalent 
cancer and is the second leading cause of cancer related 
death of men in the US [1]. It has long been known that 
androgens are critical for PCa growth and androgen 
ablation therapy is still the mainstay of treatments for 
patients with metastatic PCa. Although initially effective, 
these cancers inevitably recur as castration resistant 
prostate cancer (CRPC) for which there is still no reliable 
treatment. Deaths from PCa are primarily due to the 
development of castration resistant metastatic disease. 
Many mechanisms of CRPC have been proposed and 
studied, including but not limited to increased Androgen 
Receptor (AR) expression, crosstalk with other signaling 
pathways, AR splice variants, and variable AR cofactor 
expression [2–5]. 
Transducin beta like related 1 (TBLR1), also 
known as TBL1XR1, is a core component of the nuclear 
receptor corepressor (N-CoR) and is a silencing mediator 
of retinoic acid and thyroid receptor (SMRT) complex 
[6, 7]. A secondary isoform of TBLR1 (TBLR1β) has been 
previously  identified,  formed  from  alternative  splicing 
creating a variable C-terminus and a slightly larger protein 
of about 60 kDa [8]. As an intrinsic component of these 
corepressor complexes, TBLR1 has essential functions 
both as a corepressor and a coactivator of multiple nuclear 
receptors [9, 10]. Additionally, TBLR1 and the closely 
related TBL1X are necessary for activation of Wnt target 
genes [11]. TBL1X plays an important role in protecting 
beta catenin from degradation in the cytoplasm allowing 
for transcription of its targets genes [12]. Overexpression 
of TBLR1 inhibits growth in 293T and Jurkat cells and 
is involved in degradation of the anti-apoptotic protein 
BCL-3 [8, 13]. TBLR1 is a ubiquitously expressed 
protein [14]. Immunohistochemical data shows TBLR1 as 
primarily a nuclear protein in normal prostate but shows 
reduced nuclear expression in PCa [15]. TBLR1 is also 
a strong coactivator of AR in prostate cancer, leading 
to selective activation of growth suppressive AR target 
genes and tumor suppression. In contrast to the reduced 
expression of TBLR1 in PCa, expression of TBLR1 is 
upregulated in breast, colon, esophageal squamous cell 
and nasopharyngeal carcinomas (NPC) and is a potential 
prognostic marker for aggressive cervical cancer [16–18]. 
Overexpression of TBLR1in NPC cells causes reduced 
sensitivity to cisplatin-induced apoptosis [18].
Nuclear transport is critical for controlling 
localization and proper function of proteins. Many proteins 
exhibit different functions based on their post-translational 
modifications and cellular compartmentalization. The AR 
coactivator p44/MEP50 displays a tumor suppressor role 
in the nucleus but promotes PCa growth and prostate 
development when expressed in the cytoplasm [19]. 
Transport of proteins across cellular compartments is 
regulated at several protein and cellular levels [20], 
including nuclear localization signals (NLS) and nuclear 
export signals (NES). Common NLS sequences contain 
arginine and lysine, and NES sequences are leucine rich, 
however these cases do not appear to be universal [21, 22]. 
In this study we characterize the expression and 
function of cytoplasmic TBLR1, which is found in a 
55 kDa full length form and, in PCa, in a 50 kDa isoform 
also. We found increased cytoplasmic TBLR1 in CRPC 
and also identified a post-translational cleaved variant of 
TBLR1 localized only in the cytoplasm that is also higher 
in CRPC. We found that TBLR1 when localized in the 
cytoplasm inhibits apoptosis induced by androgen ablation 
in PCa cells. Additionally, we identified a nuclear export 
sequence within the protein necessary for its sub-cellular 
compartmentalization. This study may provide insight to 
develop effective targets for the treatment of CRPC.
RESULTS
Reduction of apoptosis by full length cytoplasmic 
TBLR1 (cTBLR1) under androgen deprivation 
Previously our lab showed that TBLR1 was 
expressed as both nuclear and cytoplasmic protein [15]. In 
PCa cells, nuclear expression of TBLR1 was significantly 
reduced in comparison to benign prostate cells. In this 
study we compared cytoplasmic expression of TBLR1 
and its function between androgen-dependent (AD) PCa 
cells and androgen-independent (AI) PCa cells. When 
comparing TBLR1 levels by western blot between AD 
LNCaP PCa cell lines and two AI PCa cell lines, LNCaP-
AI and PC-3, we found increased total level of TBLR1 
in the AI cells (Figure 1A). To determine the subcellular 
localization of the increased TBLR1 in AI cancer cell lines 
compared to AD cancer cells, we performed western blot 
analyses with fractionated nuclear and cytoplasmic cell 
lysates. We found that the increased level of TBLR1 in AI 
cancer cell lines was due to increased cytoplasmic TBLR1 
(Figure 1C, 1D).
Previously our lab showed that overexpression of 
nuclear TBLR1 in AD LNCaP cells inhibited growth in 
an androgen-dependent manner by cell cycle arrest but 
this overexpression had no effect on apoptosis [15]. To 
test the function of cytoplasmic TBLR1, we created stable 
LNCaP cell lines overexpressing TBLR1 in the cytoplasm 
utilizing a fusion construct of the nuclear export sequence 
(NES) (MLQKKLEELE) to the N-terminus of TBLR1. 
We confirmed overexpression and cytoplasmic localization 
of TBLR1 in these cells by western blot of total lysate 
(Figure 1E) and fractionated lysate (Supplementary 
Figure 1A). LNCaP cells require androgens for survival 
and in their absence, these cells undergo apoptosis [23]. 
LNCaP NESTBLR1 cells exhibited reduced cell death 
visually (Figure 1G) in androgen free media compared to 
control cells (Figure 1F). Next, we performed Caspase 3/7 
activity assays to test the effect of cytoplasmic TBLR1 
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on apoptosis in androgen-free and regular media with 
and without bicalutamide, an anti-androgen medication. 
LNCaP NESTBLR1 cells  showed  significant  reduction 
of Caspase 3/7 activity after 48 hours in androgen-free 
medium  (Figure  1H).  We  also  observed  a  significant 
reduction of Caspase 3/7 activity after 30 hours in 150 µm 
anti-androgen bicalutamide media in LNCaP NESTBLR1 
cell  (Figure  1I).  We  confirmed  reduced  apoptosis  in 
androgen-free conditions and bicalutamide-treated cells 
in LNCaP NESTBLR1 cells compared to LNCaP pBabe 
cells by TUNEL assay. Quantification of TUNEL-positive 
cells showed approximately 2.5 fold reduction for 
LNCaP NESTBLR1 cells in both conditions (Figure 1J). 
Representative pictures showing reduced TUNEL staining 
in both conditions in LNCaP NESTBLR1 cells are shown 
in Figure 1K–1L. Notably, we also tested cell proliferation 
and migration/invasion ability between LNCaP pBabe 
and LNCaP NESTBLR1 cells and we did not observe any 
difference (data not shown). The reduction in apoptosis 
by NESTBLR1 in regular medium by both assays was 
not  statistically  significant  (data  not  shown).  In  cell 
proliferation, migration and invasion assays, NESTBLR1 
did  not  show  statistically  significant  differences  when 
compared to control. 
Identification and function of 50 kDa 
cytoplasmic-specific TBLR1 isoform 
In  addition  to  full  length  TBLR1,  we  identified 
a faster migrating protein band recognized by TBLR1 
antibody that runs at approximately 50 kDa (Figure 1A). 
We consistently observed cvTBLR1 across multiple cell 
lines including LNCaP-AI, C4-2B and VCaP. To confirm 
this second observed band as a variant of TBLR1 protein, 
we transfected LNCaP-AI cells with specific siRNA for 
TBLR1.  TBLR1  specific  siRNA  reduced  expression 
of both full length and the faster migrating variant. 
Conversely, overexpression of full length TBLR1 cDNA 
by transfection into cells also led to increased cvTBLR1 
by western blot (data not shown). These data confirm the 
50 kDa band  is  a  specific TBLR1  isoform  (cvTBLR1) 
(Figure 1B). We also found that cvTBLR1 was only 
expressed in the cytoplasm and was significantly increased 
in AI cells (Figure 1C). Over expression of NES-TBLR1 
also leads to increased cvTBLR1 levels in the cytoplasm 
(Supplementary Figure 1A). 
In order to isolate and purify cvTBLR1 for analysis 
we tested different commercial TBLR1 antibodies 
for TBLR1 immunoprecipitation to identify potential 
capture antibodies specific for cvTBLR1. We used three 
different TBLR1 specific antibodies and found that each 
antibody selectively pulls down a single form of TBLR1 
(Figure 2A). Interestingly, all three of these antibodies 
recognize both forms by western blot (data not shown). 
Antibody #1, a monoclonal antibody designed from 
peptide sequence AA 81-179 of the 514 AA protein 
specifically immunoprecipitated cvTBLR1 with only small 
amounts of full length TBLR1 present. We next prepared 
large-scale immunoprecipitation preps in PC-3 cells 
using either Antibody #1 or Antibody #2 for purification. 
Pulldown of  cvTBLR1 was first  confirmed by western 
blot (Figure 2B). Antibody #1 primarily pulled down 
cvTBLR1 and post-TBLR1 IP lysate showed reduced 
levels of cvTBLR1 compared to post-IgG IP, confirming a 
very efficient capture. Colloidal coomassie blue stain was 
performed on purified protein  to be processed by mass 
spectrometry (MS) analysis (Supplementary Figure 1B). 
Purified  cvTBLR1  and  full  length  TBLR1  were 
analyzed by tryptic digestion and MS to identify and 
compare known peptide sequences present. cvTBLR1 
sequence  lacked  evidence  of  the  first  100  amino  acids 
suggesting this region of full length TBLR1 could be 
lacking in this isoform (Figure 2C). No peptides from 
the first 100 amino acids were detected by MS in three 
separate cvTBLR1 purifications (data not shown). We next 
performed MS analysis of purified full length TBLR1 to 
determine if detection of these peptides was not readily 
detected by our mass spectrometer. This analysis of 
full length TBLR1 revealed the presence of additional 
peptides up to AA 28, supporting the conclusion that this 
N-terminal region was lacking in cvTBLR1 (Figure 2D). 
To identify the exact location of the cleavage to form 
cvTBLR1, we next utilized in-gel TMPP N-terminus 
labeling of purified cvTBLR1 prior  to  tryptic digestion 
followed by MS analysis. MS analysis can recognize the 
presence of the TMPP label and identify the N-terminus 
sequence of the original protein. We found PDVVQ to 
be the N-terminus labeled peptide with P corresponding 
to amino acid 89 of TBLR1 (Figure 2E). We confirmed 
these  findings  by  N-terminal  Edman  degradation  of 
purified cvTBLR1 that also found P89 as the N-terminus 
of cvTBLR1 (Figure 2F). This N-terminus region 
contains the LisH domain critical for histone binding for 
transcriptional corepression and the F-box like domain for 
transcriptional coactivation (Figure 2G, 2H). Since AA88 
of TBLR1 is a methionine, there was a strong possibility 
that cvTBLR1 could be the product of alternate translation. 
To test for alternate translation, we created a mutant 
construct of TBLR1 altering the methionine at amino 
acid 88 into an alanine (M88A) and stably transfected 
the mutant and control plasmid into 293T cells. In both 
conditions  we  identified  increased  cvTBLR1  which 
rules out alternate translation as a method of cvTBLR1 
production (Figure 2I). Additionally, there is no evidence 
of an alternate mRNA spliced variant of this size. Together 
this data suggests that cvTBLR1 could be a proteolytic 
cleavage of full length TBLR1 or a potential alternate 
translation product. 
We next tested the function of cvTBLR1 in prostate 
cancer cells. We created a fusion construct in the pBabe 
retroviral vector of nuclear export sequence (NES)-
cvTBLR1 (AA89-514 of TBLR1) and stably transfected 
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it into LNCaP prostate cancer cells (Figure 3A). We 
tested the effect of cvTBLR1 on apoptosis in these 
cells  by  a  Caspase  3/7  assay  and  found  significant 
reduction of Caspase 3/7 activity in androgen-free and 
bicalutamide media signifying a reduction in apoptosis 
(Figure 3B, 3C). We confirmed these findings by TUNEL 
assay in androgen-free media and bicalutamide media 
(Figure 3D, 3E). Interestingly and in contrast to full 
length TBLR1, overexpression of cvTBLR1 also led 
to  a  significant  increase  in  cellular proliferation over  a 
6-day growth assay (Figure 3F). We compared migration 
and invasion ability by measurement of cells traversing 
either an uncoated porous membrane (migration) or 
matrigel-covered membrane (invasion) using serum as a 
chemoattractant. We found significantly more migrating 
and invading cells with overexpression of cvTBLR1 
(Figure 3G, 3H). 
Mutation analysis to identify nuclear export 
sequences (NES) in TBLR1 
To identify potential nuclear export sequences 
(NES), we created a series of N-terminal (C1-C7) and 
C-terminal (N1-N7) deletion mutants. Additionally, we 
used site-directed mutagenesis to alter Leucine 81 (mut1) 
or Leucine 83 (mut2) or both (mut3) to alanine. We cloned 
these constructs into a pCDNA-GFP vector to visualize 
localization by confocal microscopy after transient 
transfection into 293T cells (Figure 4A). 
After transfection, cells were counted as nuclear, 
cytoplasmic, or both (equal expression). Figure 4A 
summary shows the predominant localization for 
each construct. Cells transfected with N2 construct 
expressing amino acid (AA) 1–86 of the 514 AA 
wild type (WT) TBLR1 showed strong cytoplasmic 
expression (Figure 4B, 4F). Cells transfected with N7 
(AA1-80), however, showed stronger nuclear expression 
(Figure 4C, 4G). Interestingly, although endogenous 
TBLR1 is expressed in both the cytoplasm and nucleus 
of cells, overexpression of GFP-TBLR1 shows very 
strong cytoplasmic expression (Figure 4D, 4J). Since 
NES sequences are often leucine-rich [22] and there are 
two leucines within the AA81-86 region, we used site-
directed mutagenesis to mutate each of these leucines in 
the full length TBLR1 (mut1, mut2, mut3) and transfected 
these constructs into 293T cells. Transfection of mut1 no 
longer showed strong cytoplasmic localization of WT, 
but rather more equal distribution (Figure 4E, 4K). Mut2 
Figure 1: Expression of full length cytoplasmic TBLR1 (cTBLR1) and protease cleaved cytoplasmic variant of TBLR1 
(cvTBLR1) in prostate cancer cells. (A) Relative total expression of TBLR1 and cvTBLR1 in androgen-dependent LNCaP cells 
compared to androgen-independent LNCaP-AI and PC-3 cells. (B) Confirmation of faster migrating band (cvTBLR1) as a TBLR1 variant 
by knockdown with TBLR1 specific  siRNA  in LNCaP-AI cells.  (C) Relative expression and localization of TBLR1 and cvTBLR1 in 
prostate cancer cells by western blot of fractionated lysates. (D) Quantification of fractionation western blot comparing localization and 
relative expression of TBLR1 and cvTBLR1 in prostate cancer cells. (E) Overexpression of cytoplasmic TBLR1 using nuclear export 
sequence (NES) fused TBLR1 construct to create LNCaP –NESTBLR1 cells. (F) LNCaP pBabe cells after 6 days in hormone free media. 
(G) LNCaP NESTBLR1 cells after 6 days in hormone free media.  (H) Caspase 3/7 luciferase assay measuring apoptosis in LNCaP 
pBabe and LNCaP NESTBLR1 cells in hormone free media. (I) Caspase 3/7 luciferase assay measuring apoptosis in LNCaP pBabe and 
LNCaP NESTBLR1 cells in 150 µM bicalutamide media. (J) Quantification of the percentage of TUNEL-positive cells of LNCaP pBabe 
vs. LNCaP NESTBLR1 cells in hormone free media or 150 µM bicalutamide media. (K) TUNEL staining on LNCaP control vs. LNCaP 
NESTBLR1 cells in androgen free and androgen media with (L) 150 µM bicalutamide treatment.  
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Figure 2:  Sequence identification of cvTBLR1. (A) Immunoprecipitation with three different TBLR1 specific antibodies to identify 
antibody to purify cvTBLR1. (B) Large scale purification of cvTBLR1 using antibody #1 and full length TBLR1 using antibody #2 for 
mass spectrometry (MS) sequencing. (C) TBLR1 sequence showing bold/highlighted sequences of peptides identified by MS from purified 
cvTBLR1. (D) TBLR1  sequence  showing  bold/highlighted  sequences  of  peptides  identified  by MS  from purified  full  length TBLR1.  
(E) Identification of N-terminal sequence of cvTBLR1 using TMPP labeled purified cvTBLR1 followed by MS sequence analysis.  MS/MS 
spectrum of the doubly charged N-terminal peptide PDVVQTR of cvTBLR1 is shown, with the peptide sequence with annotation of the 
matched ions above the spectrum. (F) Confirmation of N-terminus of cvTBLR1 by Edman degradation analysis of the protein, overlay plot 
of the first five cycles. Y axis is millivolts.  Absorbance is measured at 269 nm.  Color code for the chromatogram matches the colors of the 
text reporting the identified amino acids. (G) Diagram of conserved domains in full length TBLR1. (H) Diagram of cvTBLR1 lacking the 
LisH and F-box domains of full length TBLR1 important for transcriptional regulation. (I) Overexpression of wildtype or mutated M88A 
full length TBLR1 shows increased cvTBLR1 in both conditions. 
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and mut3 also showed nuclear predominant localization 
(Figure 4L– 4M). Quantification of  the number of cells 
with nuclear or cytoplasmic TBLR1 localization of 
additional constructs is located in Supplementary Figure 2. 
Together this data confirms AA81 and AA83 are important 
residues for a strong NES in TBLR1. 
DISCUSSION
TBLR1  was  originally  identified  as  an  integral 
component of the NCOR/SMRT co-repressor complex. 
Subsequently, it was found that TBLR1 can also act 
as a transcriptional activator for nuclear hormone 
receptors and regulated transcription factors. TBLR1 is 
overexpressed in several types of cancer and functions 
as an oncogene by activation of important intracellular 
signaling  pathways  including  the  Wnt-β-catenin 
pathway and the nuclear factor-kappa (NF-kB) pathway 
[11, 24]. TBLR1 expression has a positive correlation 
with disease progression, tumor metastasis, and drug 
resistance [16–18, 25–27]. Our previous study has 
shown that TBLR1 is a transcriptional activator of AR 
and its nuclear expression is significantly reduced in PCa 
compared with benign prostate glands. Forced expression 
of nuclear TBLR1 leads to androgen-dependent growth 
suppression of prostate cancer cells in vitro and in vivo 
by selective activation of androgen-regulated genes 
associated with differentiation and growth suppression 
[15]. In addition to its nuclear localization, TBLR1 can 
also be a cytoplasmic protein. TBLR1 is predominantly 
located in the cytoplasm of LNCaP-AI cells in complete 
media but serum starvation induces its translocation into 
nucleus. These findings suggest that cytoplasmic TBLR1 
may play an important role distinct from that of nuclear 
TBLR1. However, the functionality in most past TBLR1 
studies did not clarify if the effects were due to nuclear or 
cytoplasmic TBLR1. 
In this study, we found that the total level of TBLR1 
protein is increased in AI PCa cell lines compared to an 
AD PCa cell line. For example, cytoplasmic TBLR1 is 
expressed at a higher level in both LNCaP-AI and PC-3 
cells compared to LNCaP cells. We also identified a novel 
TBLR1 variant-cvTBLR1. It is exclusively located in 
cytoplasm and expressed at a much higher level in AI 
PCa cells than in AD PCa cells. In theory, the cvTBLR1 
could be the product of alternative splicing, alternative 
translation or proteolytic cleavage. However, it is very 
interesting that when we stably overexpressed full length 
TBLR1 cDNA, PCa cells also showed increased presence 
of cvTBLR1. This provided evidence against formation 
of cvTBLR1 by alternate splicing and evidence for post-
translational formation. Due to cvTBLR1 pro-proliferative 
and anti-apoptotic roles, stable overexpression of TBLR1 
may lead to selective pressure on cells to increase 
formation of cvTBLR1. This appears to be a slow 
process, since we have not observed a noticeable increase 
in cvTBLR1 with transient overexpression of full length 
TBLR1. 
We were able to isolate cvTBLR1 by taking 
advantage of an interesting observation that the TBLR1 
antibodies we used to purify cvTBL1 exhibited different 
specificities.  While  all  TBLR1  antibodies  detected 
both forms on western blot, the TBLR1 antibody from 
Abcam preferentially pulled down only cvTBLR1 by 
immunoprecipitation. A possible explanation is that 
cvTBLR1 has a tertiary structure different from that 
of full length TBLR1, which makes certain epitopes 
accessible for this antibody. As a result, this change 
may be responsible for the localization and functions of 
cvTBLR1. Mass spectrometric analysis of the TMPP-
labeled purified cvTBLR1protein showed that it lacks the 
first 88 amino acids of TBLR1. To support that cvTBLR1 
is  a  product  of  proteolytic  cleavage,  we  identified  by 
Edman degradation the N-terminus of cvTBLR1 as 
PDVVQ, a peptide sequence located between amino acid 
89 and 93 of TBLR1. This site is conserved in proteolytic 
cleavage sites [28]. There is a methionine at amino acid 88 
of TBLR1 suggesting that cvTBLR1 could be a product 
of alternative translation. We created a TBLR1 mutant 
that has an alanine replacing the methionine at amino acid 
88, destroying the second translation initiation site. When 
the mutant is expressed, the levels of full-length TBLR1 
and cvTBLR1 are still both increased, which provides 
strong evidence that cvTBLR1 is not due to alternative 
translation. 
Our previous study showed that overexpression 
of nuclear TBLR1 inhibited LNCaP cell growth in 
an androgen-dependent manner by cell cycle arrest 
but had no effect on apoptosis [15]. In contrast, this 
study demonstrates that overexpression of cytoplasmic 
TBLR1,  both  full  length  and  cvTBLR1,  significantly 
reduces apoptosis when measured by both fluorescent 
Caspase 3/7 assays and Tunel experiments, consistent 
with recent reports suggesting TBLR1 mediates 
antiapoptotic  effects  [18].  Most  significantly,  the 
inhibition of apoptosis is more dramatic in the androgen-
deprived condition, either in androgen-free medium 
or in the presence of the anti-androgen, bicalutamide. 
These findings suggest distinct functions of nuclear and 
cytoplasmic TBLR1. 
TBLR1 contains a conserved F-box-like domain 
that associates with Skp1 in ubiquitin-dependent 
protein degradation. In Drosophila Ebi, the homolog 
of TBL1 and TBLR1, binds Tramtrack and promotes 
its  degradation  [29,  30].  The  canonical  Wnt/β-
catenin pathway plays an important role in prostate 
tumorigenesis  and  is  significantly  mutated  in  CRPC. 
The level of β-catenin is regulated by two mechanisms: 
the adenomatous polyposis coli/Axin/glycogen synthase 
kinase 3 beta-dependent degradation pathway and 
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Figure 3: Function of cvTBLR1. (A) Overexpression of cvTBLR1 using nuclear export sequence (NES) fused cvTBLR1 (AA89-
514) construct to create LNCaP –NEScvTBLR1 cells. (B) Caspase 3/7 luciferase assay measuring apoptosis in LNCaP pBabe and 
LNCaP NEScvTBLR1 cells in hormone free media. (C) Caspase 3/7 luciferase assay measuring apoptosis in LNCaP pBabe and LNCaP 
NEScvTBLR1 cells in 150 µM bicalutamide media. (D) Quantification  of  the  percentage  of TUNEL-positive  cells  of  LNCaP  pBabe 
vs. LNCaP NEScvTBLR1 cells in hormone free media. (E) Quantification of the percentage of TUNEL-positive cells of LNCaP pBabe 
vs. LNCaP NEScvTBLR1 cells in 150 µM bicalutamide media. (F) Cellular proliferation comparison of LNCaP pBabe vs. LNCaP 
NEScvTBLR1 cells over 6 days by CCK-8 assay. (G) Migration assay of LNCaP-NEScvTBLR1 compared to LNCaP pBabe control. 
(H) Invasion assay of LNCaP-NEScvTBLR1 compared to LNCaP pBabe control and representative pictures of membrane.
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the Siah-1/Siah interacting protein/Ebi-mediated 
degradation pathway. Ebi(ΔF), which  lacks  the F-box 
domain and retains ability to bind β-catenin, is capable of 
preventing the Sial-induced downregulation of β-catenin 
and TCF/LEF1 activity [31]. cvTBLR1 also lacks the 
N-terminal F-box like region of full length TBLR1. 
Given the high structural similarity between cvTBLR1 
and Ebi(ΔF), the overexpression of cvTBLR1 in AI PCa 
cells suggest that cvTBLR1 may function as a dominant 
negative form to inhibit β-catenin degradation and thus 
induce cytoplasmic accumulation of β-catenin and TCF/
LEF activity. Further, it was shown that TBL1/TBLR1 
can bind β-catenin and the interaction is required for its 
translocation into the nucleus [11]. It is of great interest 
to investigate the link between cvTBLR1 and β-catenin 
and TCF/LEF1 pathway in future studies. 
Finally, we identified a NES for cytoplasmic 
localization of TBLR1 at the N-terminus which 
contains two conserved leucine residues. By targeting 
these sites, we may be able to develop approaches to 
switch the cellular localization, thus the functions of 
TBLR1. 
In conclusion, TBLR1 appears to be a 
multifunctional protein important for many cellular 
processes. In this study, we demonstrate that cytoplasmic 
TBLR1 is increased in CRPC cells. We also identify a 
novel TBLR1 variant that is potentially a proteolytic 
product, higher in CRPC, and promotes growth, invasion, 
and antiapotosis. Both full length and and cvTBLR1 may 
play a pivotal role in castration resistance of PCa. It will 
be of great interest to investigate the TBLR1 cytoplasmic 
forms in CRPC in the future. 
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Figure 4: Identification of TBLR1 localization sequences by deletion mutation analysis. (A) Diagram of GFP-TBLR1 
mutant constructs designed and summary of primary localization of transfected GFP fusion mutant construct. (B–E) Fluorescence image, 
Hoescht stain, and merged image of 293T cells transfected with GFP-TBLR1 mutant constructs N2, N7, wild type, and mutant L81A. 
(F–M) Quantification of TBLR1 localization observed in 293T cells transfected with mutant GFP-TBLR1 constructs.  Cells showing GFP 
expression by fluorescent imaging were counted as cytoplasmic, nuclear, or both for expression.
Oncotarget39568www.impactjournals.com/oncotarget
MATERIALS AND METHODS
Cell culture
LNCaP, LNCaP-AI, PC-3, and 293T cells were 
maintained in complete medium (RPMI medium 1640 
(High glucose DMEM for 293T) plus 10% FBS), 
androgen-free medium (phenol-free RPMI medium with 
charcoal-treated FBS), or androgen media (androgen-free 
medium with 10 nM R1881). LNCaP-AI, an androgen-
independent derivative of LNCaP, was from the laboratory 
of Dr. A. Ferrari (New York University Cancer Institute) 
[32]. LNCaP, PC-3, and 293T cells were procured from 
ATCC (Manassas, VA, USA) with documentation of 
authentication by STR analysis. Passages from 5 to 20 of 
each cell line were used for experiments. Cell lines were 
maintained at 37°C with 5% CO2. All cell culture materials 
were ordered from Life Technologies.
Whole cell lysates, cell fractionation, and 
immunoblot analysis
Whole-cell extracts were prepared from LNCaP, 
LNCaP-AI, and PC-3 cells in RIPA buffer (50 mM Tris-
HCl ph 8.0, 150 mM NaCl, 1% NP-40, 1 mM EDTA, 
0.1% SDS). For cell fractionation, cells were lysed with 
cytoplasmic buffer (10 mM HEPES ph 7.6, 50 mM NaCl, 
0.5 M sucrose, 1 mM DTT, 5 mM MgCl2, 0.1% Triton 
X-100). After centrifugation, the supernatant was the 
cytoplasmic fraction and the nuclear pellet was washed 
3 times with cytoplasmic buffer followed by lysis with 
RIPA buffer. Extracts were subjected to electrophoresis 
on SDS/PAGE and then transferred to nitrocellulose 
membranes for immunoblot analysis as described [33]. 
Antibodies for TBLR1#1 (sc-100908) were purchased 
from Santa Cruz antibodies. Antibodies for H2B and 
GAPDH were purchased from Cell Signaling. Antibodies 
for TBLR1#2 (ab24550) and TBLR1#3 (ab84141) were 
purchased from Abcam. 
Protein purification and edman degradation
Initial immunoprecipitation of TBLR1 was 
performed with three separate antibodies described 
above. Cells were lysed with 50 mM Tris pH 8.0, 
150 mM NaCl, 1 mM EDTA, 0.5% NP-40 buffer for 
20  minutes  on  ice.  Lysates  were  clarified  by  centri-
fugation for 20 minutes at 13000 rpm at 4°C. Clarified 
lysates were incubated with 2 µg of TBLR1 or IgG 
control antibody overnight at 4°C, followed by addition 
of 20 µl Dynabeads Protein G (Invitrogen) washed with 
lysis buffer for 4 hours at 4°C. Immunoprecipitated 
material was washed 4× with lysis buffer and eluted 
with 2× Laemmli buffer at 37°C for 5 minutes. 
Large  scale  50  kDa  TBLR1  isoform  purification  by 
immunoprecipitation for mass spectrometry with and 
without TMPP labeling or Edman degradation for 
N-terminus analysis were performed as above except 
after clarification and before addition of antibody NaCl 
was added to bring final NaCl concentration to 300 mM 
to further purify immunoprecipitate. Protein gels for 
mass spectrometry were stained with Novex colloidal 
blue staining kit (Invitrogen) per manufacturer’s 
intructions. For Edman degradation, protein gels were 
transferred to PVDF membrane as described previously 
[33], as membranes were stained by colloidal blue 
staining kit (Invitrogen). Protein transferred to PVDF 
was analyzed by automated Edman degradation in 
the Protein Structure Core Facility, University of 
Nebraska Medical Center, using a Procise 494 protein 
sequencer (ABI). All reagents were purchased from Life 
Technologies. 
TMPP labeling and mass spectrometry of 
TBLR1
Excised gel bands were reduced, alkylated and 
dried. Protein was then digested with trypsin (Promega) 
overnight at 37°C. Digested peptides were extracted, 
desalted and analyzed by LC-MS/MS (Q Exactive, 
Thermo Electron). Raw data were used to search with 
Mascot Distiller a small custom database containing 176 
protein sequences including TBLR1. Protein N-terminal 
identification was  performed  as  described  in  [34]. Ten 
microliters of 0.1 M of (N-succinimidyloxycarbonyl-
methyl) tris (2, 4, 6-trimethoxyphenyl) phosphonium 
bromide (TMPP-Ac-OSu) (Sigma) in acetonitrile were 
added to gel pieces and incubated overnight. Protein was 
then digested with trypsin in TEAB buffer (Promega) 
overnight at 37°C. Digested peptides were extracted, 
desalted and analyzed by LC-MS/MS (Q Exactive, 
Thermo Electron). Raw data were searched without 
enzyme restriction.
Construction of retroviral pBabe vectors 
expressing NESTBLR1 or NEScvTBLR1 to 
construct stable cell lines
A TBLR1 fusion protein was created in which the 
strong NES (MLQKKLEELE) was fused to the N terminus 
of TBLR1 to create NESTBLR1. An additional fusion 
protein was created in which the strong NES was fused to 
the sequence of AA89-514 from full length TBLR1 to create 
NEScvTBLR1. Both fusion proteins were cloned into the 
pBabe Puro retroviral vector as described previously [19]. 
Briefly, Phoenix A amphotropic packaging cells (American 
Type Culture Collection) were transfected with NESTBLR1, 
NEScvTBLR1 and pBabe retroviral constructs to produce 
virus. The virus-containing supernatant was collected by 
centrifugation and filtered before retroviral infection. Stable 
cell lines were selected in 1 µg/mL puromycin.
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Apoptosis assays
Promega luciferase Apoptosis was measured 
by Caspase-GLO 3/7 assay (Promega) on cells after 
treatment with 150 µm bicalutamide or DMSO control 
for 30 hours or hormone free or 10 nM R1881 for 
72 hours. Luciferase readings were read on Berthold 
Lumat LB 9507. The TUNEL assay was performed using 
Click- iT® TUNEL Alexa Fluor® Imaging Kit (Invitrogen) 
in accordance with the manufacturer’s protocol. In 
brief,  cells  were  fixed  with  4%  paraformaldehyde  in 
PBS at room temperature for 20 min and permeabilized 
with Triton X-100 (0.25% in PBS) for another 20 min. 
The cells were washed twice and incubated with 
terminal deoxynucleotidyl transferase reaction buffer 
(Component A) for 10 min at room temperature. The 
buffer was removed and the TUNEL reaction mixture 
containing terminal deoxynucleotidyl transferase was 
added, incubating the cells  in a humidified chamber at 
37°C for 60 min. Then, cells were washed three times 
with 3% BSA in PBS for 2 min each and then incubated 
with Click-iT reaction mixture (containing Alexa 488 
azide) for 30 min at room temperature, while being 
protected from light exposure. The cells were again 
washed with 3% BSA in PBS and the cell nuclei were 
counterstained with Hoechst 33342 for 15 min at room 
temperature, protected from light. The coverslips were 
washed twice with PBS before mounting onto a slide 
with mounting medium. The TUNEL-positive cells were 
counted in eight different, random fields for each well.
Deletion and site-directed mutagenesis
TBLR1 C-terminus deletions (N1, N2, N3, N4, N5, 
N6 and N7), N-terminus deletions (C1, C2, C3, C4, C5, 
C6, C7 and C8), and both terminus deletions (M1 and 
M2), were generated by PCR and cloned into pCR2.1-
TOPO vectors (TOPO TA Cloning kit, 450641, Life 
Technologies). These deletions were then subcloned into 
pcDNA3.1 (+) with GFP plasmid. pcDNA3.1 TBLR1 
point mutations (Mut1, Mut2 and Mut3) were generated 
using QuickChange II XL Site-Directed Mutagenesis 
Kit (200521, Stratagene). Mut1 is Leu81Ala, Mut2 is 
Leu83Ala and Mut3 is Leu81&83Ala. QuickChange II XL 
was also used to create TBLR1 M88A mutant construct. 
The list of primers used to generate these clones in 
Supplementary Table 1.
Confocal microscopy
To evaluate the intracellular localization of TBLR1 
deletions and site-directed mutants, 293 cells were seeded 
in each well of 4 well chamber slides w/cover glass slide 
(154534, Thermo Fisher Scientific) and transfected with 
0.5 µg DNA of GFP-TBLR1 constructs as indicated. At 
24 hr, NucBlue Live Cell Stain ReadyProbes Reagent 
Hoechst33342 (R37605, Life Technologies) were added 
to the medium and cells were incubated for 20 min at 
20– 25°C. Fluorescent images of live cells were obtained 
with a Zeiss LSM710 confocal microscope imaging 
system and analyzed with ImageJ software.
Enumeration of percentage of cells for nuclear 
and cytoplasmic localization
293T cells were seeded in three wells of a 4 well 
chamber  slide  (155382,  Thermo  Fisher  Scientific)  and 
transfected with 0.5 ug DNA of GFP-TBLR1 constructs 
in triplicate. At 24 hr, subcellular localization of TBLR1 
and mutants was examined with a Nikon Eclipse TS100 
fluorescent microscope and a Nikon DXM1200F digital 
camera. A minimum of 100 cells per well were recorded 
from each of three wells. Localization in each individual 
cell was determined based on comparison of intensities 
between cytoplasmic and nuclear GFP, and therefore 
categorized into nuclear expression, cytoplasmic 
expression and both nuclear and cytoplasmic expression. 
Percentage of cells in each category was calculated. 
Results are expressed as mean + standard error. 
Growth, migration, and invasion assays
For growth assay, cells were seeded in 24 well 
plates at 1 × 104 cells/well. Cell growth was monitored 
every 2 days by addition of 50 µl of CCK-8 reagent 
(Sigma Life Sciences) to the well, incubated at 37°C 
for 1 hour and absorbance was measured at 450 nm. 
For migration and invasion assays, cells (5 × 104) were 
plated into Corning Biocoat Matrigel invasion chambers 
or chambers with no matrigel for migration in triplicate 
without serum. 10% FBS media was used as an attractant 
in the lower chamber and cells were incubated for 
24  hours. Membranes were  fixed, washed  and  stained 
with  a Three Step Stain Kit  (Richard-Allan Scientific) 
and three representative regions of each membrane were 
counted under the microscope.
Statistical analysis 
Statistical analyses of the above results were 
performed by pairwise Student’s t test. Differences are 
considered statistically significant if p < 0.05.
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